Effects of a low-fat diet on the hepatic expression of adiponectin and its receptors in rats with NAFLD

Annals of Hepatology

Volumn 14, Issue 1, 2015, Pages 108-117

  Ma, Hong ^a,b   You, Guo Ping ^b   Cui, Fan ^a   Chen, Lu Fang ^a,b   Yang, Xiang Jiu ^a   Chen, Li Gang ^a   Lu, Hua Dong ^a   Zhang, Wen Qiang ^a  

^a ZHONGSHAN HOSPITAL OF XIAMEN UNIVERSITY   (China)

^b FUJIAN MEDICAL UNIVERSITY   (China)

Author keywords

Adipokine; Dietary intervention; Fatty liver; Pathogenesis; Pathology

Indexed keywords

ADIPONECTIN; ADIPONECTIN RECEPTOR 1; ADIPONECTIN RECEPTOR 2; ADIPONECTIN RECEPTOR; ADIPONECTIN RECEPTOR 1, RAT; ADIPONECTIN RECEPTOR 2, RAT; ADIPOQ PROTEIN, RAT; ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; MESSENGER RNA;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DISEASE COURSE; INFLAMMATION; LIPID DIET; LIVER FATTY DEGENERATION; LOW FAT DIET; MALE; NONALCOHOLIC FATTY LIVER; NONALCOHOLIC FATTY LIVER DISEASE ACTIVITY SCORE; NONHUMAN; PROTEIN EXPRESSION; RAT; RECEPTOR DOWN REGULATION; THERAPY EFFECT; UPREGULATION; ANIMAL; BLOOD; DIET THERAPY; GENETICS; LIVER; METABOLISM; PATHOLOGY; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION;

ADIPONECTIN; ALANINE TRANSAMINASE; ANIMALS; ASPARTATE AMINOTRANSFERASES; DIET, FAT-RESTRICTED; DIET, HIGH-FAT; LIVER; MALE; NON-ALCOHOLIC FATTY LIVER DISEASE; RATS; RECEPTORS, ADIPONECTIN; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER;

EID: 84918777373     PISSN: 16652681     EISSN: None     Source Type: Journal    
DOI: 10.1016/s1665-2681(19)30807-5     Document Type: Article

References (32)

1. Mazza A, Fruci B, Garinis GA, Giuliano S, Malaguarnera R, Belfiore A. The role of metformin in the management of NAFLD. Exp Diabetes Res 2012; 2012: 716404.
2. de Alwis NM, Day CP. Non-alcoholic fatty liver disease: the mist gradually clears. J Hepatol 2008; 48(Suppl. 1): s104- 112.
3. Farrell GC, Larter CZ. Nonalcoholic fatty liver disease: from steatosis to cirrhosis. Hepatology 2006; 43(2, Suppl. 1): S99-S112.
4. Hajiaghamohammadi AA, Ziaee A, Oveisi S, Masroor H. Effects of Metformin, Pioglitazone, and Silymarin Treatment on Non- Alcoholic Fatty Liver Disease: A Randomized Controlled Pilot Study. Hepat Mon 2012; 12(8): e6099.
5. Marchesini G. Nonalcoholic fatty liver, steatohepatitis, and the metabolic syndrome. Hepatology 2003; 37: 917-23.
6. Bellentani S, Dalle Grave R, Suppini A, Marchesini G. Behavior therapy for nonalcoholic fatty liver disease: The need for a multidisciplinary approach. Hepatology 2007; 47: 746-54.
7. Angela M, Zivkovic, J Bruce German, Sanyal AJ. Comparative review of diets for the metabolic syndrome: implications for nonalcoholic fatty liver disease. AM J Clin Nutr 2007; 86: 285-300.
8. Mensink RP, Plat J, Schrauwen P. Diet and nonalcoholic fatty liver disease. Curr Opin Lipidol 2008; 19: 25-9.
9. Asrih M, Jornayvaz FR. Diets and nonalcoholic fatty liver disease: The good and the bad. Clinical Nutrition 2014; 33: 186-90.
10. Sullivan S. Implications of diet on nonalcoholic fatty liver disease. Curr Opin Gastroenterol 2010; 26: 160-4.
11. Kadowaki T, Yamauchi T, Kubota N, Hara K, Ueki K, Tobe K. Adiponectin and adiponectin receptors in insulin resistance, diabetes, and the metabolic syndrome. J Clin Invest 2006; 116: 1784-92.
12. Cnop M, Havel PJ, Utzschneider KM, Carr DB, Sinha MK, Boyko EJ, Retzlaff BM, et al. Relationship of adiponectin to body fat distribution, insulin sensitivity and plasma lipoproteins: evidence for independent roles of age and sex. Diabetologia 2003; 46: 459-69.
13. Hivert MF, Sullivan LM, Fox CS, Nathan DM, D'Agostino RB, Sr., Wilson PW, Meigs JB. Associations of adiponectin, resistin, and tumor necrosis factor-alpha with insulin resistance. J Clin Endocrinol Metab 2008; 93: 3165-72.
14. Li SS, Shin HJ, Ding EL, van Dam RM. Adiponectin Levels and Risk of Type 2 Diabetes. Clinical Review 2009; 302: 179-88.
15. Arita Y, Kihara S, Ouchi N, Takahashi M, Maeda K, Miyagawa J, Hotta K, et al. Paradoxical decrease of an adipose- specific protein, adiponectin, in obesity. 1999. Biochem Biophys Res Commun 2012; 425: 560-4.
16. Yamauchi T, Kamon J, lto Y, Tsuchida A, Yokomizo T. Cloning of adiponectin receptors that mediate antidiabetic metabolic effects. Nature 2003; 423: 762-9.
17. Yoon MJ, Lee GY, Chung JJ, Ahn YH, Hong SH, Kim JB. Adiponectin increases fatty acid oxidation in skeletal muscle cells by sequential activation of AMP-activated protein kinase, p38 mitogen-activated protein kinase, and peroxisome proliferator-activated receptor alpha. Diabetes 2006; 55: 2562-70.
18. Yamauchi T, Kamon J, Minokoshi Y, Ito Y, Waki H, Uchida S, Yamashita S, et al. Adiponectin stimulates glucose utilization and fatty-acid oxidation by activating AMP-activated protein kinase. Nat Med 2002; 8: 1288-95.
19. Polak J, Kovacova Z, Jacek M, Klimcakova E, Kovacikova M, Vitkova M, Kuda O, et al. An increase in plasma adiponectin multimeric complexes follows hypocaloric diet-induced weight loss in obese and overweight pre-menopausal women. Clin Sci (Lond) 2007; 112: 557-65.
20. Engl J, Bobbert T, Ciardi C, Laimer M, Tatarczyk T, Kaser S, Weiss H. Effects of Pronounced Weight Loss on Adiponectin Oligomer Composition and Metabolic Parameters. Obesity 2007; 15: 1172-8.
21. Kaser S, Moschen A, Cayon A, Kaser A, Crespo J, Pons-Romero F, Ebenbichler CF, et al. Adiponectin and its receptors in non-alcoholic steatohepatitis. Gut 2005; 54: 117-21.
22. Shimizu A, Takamura T, Matsuzawa N, Nakamura S, Nabemoto S, Takeshita Y, Misu H, et al. Regulation of adiponectin receptor expression in human liver and a hepatocyte cell line. Metabolism 2007; 56: 1478-85.
23. Fan JG, Jia JD, Li YM, Wang BY, Lu LG, Shi JP, Chan LY. Guidelines for the diagnosis and management of nonalcoholic fatty liver disease: update 2010: (published in Chinese on Chinese Journal of Hepatology 2010; 18: 163-166). J Dig Dis 2011; 12: 38-44.
24. Deepa SS, Dong LQ. APPL1: role in adiponectin signaling and beyond. Am J Physiol Endocrinol Metab 2009; 296(1): E22-E36.
25. Kadowaki T, Yamauchi T. Adiponectin and Adiponectin Receptors. Endocr Rev 2005; 26: 439-51.
26. Fock KM, Khoo J. Diet and exercise in management of obesity and overweight. J Gastroenterol Hepatol 2013; 28: 59-63.
27. Clark JM. Weight loss as a treatment for nonalcoholic fatty liver disease. J Clin Gastroenterol 2006; 40: s39- s43.
28. Madsen EL, Rissanen A, Bruun JM, Skogstrand K, Tonstad S, Hougaard DM, Richelsen B. Weight loss larger than 10% is needed for general improvement of levels of circulating adiponectin and markers of inflammation in obese subjects: a 3-year weight loss study. Eur J Endocrinol 2008; 158: 179-87.
29. Torres DM, Harrison SA. Diagnosis and therapy of nonalcoholic steatohepatitis. Gastroenterology 2008; 134: 1682-98.
30. Perito ER, Rodriguez LA, Lustig RH. Dietary treatment of nonalcoholic steatohepatitis. Curr Opin Gastroenterol 2013; 29: 170-6.
31. Buechler C, Wanninger J, Neumeier M. Adiponectin, a key adipokine in obesity related liver diseases. World J Gastroenterol 2011; 17: 2801-11.
32. Ma H, You GP, Zhang XP, Yang XJ, Lu HD, Huang YL, Zhang WQ. A novel role of globular adiponectin in treatment with HFD/STZ induced T2DM combined with NAFLD rats. Scientific World Journal 2014; 2014: 1-7.